Clinical Trials · NCT07881783
A Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy
Not Yet RecruitingN/ATirzepatide (Investigational)Semaglutide (Investigational)Liraglutide (Investigational)Dulaglutide (Investigational)Exenatide (Investigational)Lixisenatide (Investigational)
- Phase
- N/A
- Recruitment status
- Not Yet Recruiting
- Sponsor
- Novartis Pharmaceuticals
- Enrollment
- 3,718
- Start date
- Oct 2026
- Locations
- See registry
- Primary endpoint
- Time to Secukinumab Treatment Discontinuation During the First 12 Months of Follow-up